BG C137
Alternative Names: BG-C137; FGFR2b ADC - BeOne MedicinesLatest Information Update: 14 Jun 2025
At a glance
- Originator BeiGene
- Developer BeOne Medicines
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Gastrointestinal cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 09 Dec 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, China, Australia (IV) (NCT06625593)
- 03 Oct 2024 BeiGene plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease; Second-line therapy or greater) in November 2024 (IV) (NCT06625593)